Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma

被引:2
|
作者
Nakayama, Sayuka [1 ]
Masuda, Hiroko [1 ]
Miura, Sakiko [2 ]
Kuwayama, Takashi [1 ]
Hashimoto, Rikako [1 ]
Taruno, Kanae [1 ]
Sawada, Terumasa [3 ]
Akashi-Tanaka, Sadako [1 ]
Nakamura, Seigo [1 ]
机构
[1] Showa Univ Hosp, Dept Breast Surg Oncol, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428666, Japan
[2] NTT Med Ctr Tokyo, Dept Diagnost Pathol, Tokyo, Japan
[3] NTT Med Ctr Tokyo, Dept Breast Surg Oncol, Tokyo, Japan
关键词
Ductal carcinoma in situ; LORETTA trial; Low-grade DCIS; Overtreatment; Active surveillance; CORE-NEEDLE BIOPSY; LYMPH-NODE BIOPSY; BREAST-CANCER; KI-67; EXPRESSION; PREDICTORS; UNDERESTIMATION; MAMMOGRAPHY; METASTASIS; RECURRENCE; MANAGEMENT;
D O I
10.1007/s12282-022-01338-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Prospective cohort studies are being conducted worldwide to identify a low-grade group of ductal carcinoma in situ (DCIS) that does not require surgery. However, to do this, it is necessary to predict which cases, diagnosed with preoperative DCIS, will be upgraded to invasive ductal carcinoma (IDC) after surgery. Methods In this study, we evaluated the frequency of IDC upgrades in patients who were preoperatively diagnosed with DCIS at Showa University using the criteria of ongoing clinical trials. We divided our cases into those that could be enrolled in the ongoing trial and those that could not. Moreover, we evaluated whether CNB, which is allowed only in Japanese clinical trials, is related to the IDC mixture. Results There were 211 (52.1%) cases that matched the criteria of the U.K. and Netherlands trials, of which 62 (29.4%) were upgraded to IDC. A total of 113 (27.9%) cases met the criteria for clinical trials in Japan and the U.S., 25 (22.1%) of which were upgraded to IDC and 47 (34.6%) which matched when considering biopsy methods. The number of cases upgraded to IDC decreased to four (8.5%). Conclusions This study demonstrated that there were a certain number of mixed IDC. We will pay attention to the results of ongoing clinical trials regarding how the presence of this mixed IDC affects the prognosis in non-surgery cases. Careful follow-up is recommended for non-surgical treatment.
引用
收藏
页码:610 / 617
页数:8
相关论文
共 50 条
  • [41] Lumpectomy surgery for large ductal carcinoma in situ
    Padilla, Daniela Bresciani
    Tsai, Jacqueline
    Beck, Amanda Sutherland
    Wapnir, Irene L.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 51 - 58
  • [42] Insights into the transition of ductal carcinoma in situ to invasive ductal carcinoma: morphology, molecular portraits, and the tumor microenvironment
    Chen, Weiling
    Wang, Guimei
    Zhang, Guojun
    CANCER BIOLOGY & MEDICINE, 2022, 19 (10) : 1487 - 1495
  • [43] Exploring Ductal Carcinoma In-Situ to Invasive Ductal Carcinoma Transitions Using Energy Minimization Principles
    Sheraton, Vivek M.
    Ma, Shijun
    COMPUTATIONAL SCIENCE - ICCS 2022, PT I, 2022, : 375 - 388
  • [44] Glucocorticoids promote transition of ductal carcinoma in situ to invasive ductal carcinoma by inducing myoepithelial cell apoptosis
    Zubeldia-Plazaola, Arantzazu
    Recalde-Percaz, Leire
    Moragas, Nuria
    Alcaraz, Mireia
    Chen, Xieng
    Mancino, Mario
    Fernandez-Nogueira, Patricia
    Prats de Puig, Miquel
    Guzman, Flavia
    Noguera-Castells, Aleix
    Lopez-Plana, Anna
    Enreig, Estel
    Carbo, Neus
    Almendro, Vanessa
    Gascon, Pedro
    Bragado, Paloma
    Fuster, Gemma
    BREAST CANCER RESEARCH, 2018, 20
  • [45] Is radiotherapy necessary for intermediate risk ductal carcinoma in situ after breast conserving surgery?
    Kim, Taeryung
    Park, Heung Kyu
    Lee, Kyung Hee
    Kim, Kwan Il
    Lee, Kyu Chan
    Ahn, Jeong Suk
    Ko, Kwang-Pil
    SPRINGERPLUS, 2015, 3 : 1 - 9
  • [46] Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast
    Kim, Milim
    Chung, Yul Ri
    Kim, Hyun Jeong
    Woo, Ji Won
    Ahn, Soomin
    Park, So Yeon
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [47] Angiogenesis and invasive recurrence in ductal carcinoma in situ of the breast
    Teo, NB
    Shoker, BS
    Jarvis, C
    Martin, L
    Sloane, JP
    Holcombe, C
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (01) : 38 - 44
  • [48] Factors Predicting Microinvasion in Ductal Carcinoma in situ
    Ozkan-Gurdal, Sibel
    Cabioglu, Neslihan
    Ozcinar, Beyza
    Muslumanoglu, Mahmut
    Ozmen, Vahit
    Kecer, Mustafa
    Yavuz, Ekrem
    Igci, Abdullah
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (01) : 55 - 60
  • [49] Can tumor-associated macrophages in ductal carcinoma in situ on biopsy predict invasive carcinoma on excision?
    Hoskoppal, Deepthi
    Reisenbichler, Emily S.
    HUMAN PATHOLOGY, 2018, 82 : 158 - 162
  • [50] Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes
    Goh, Chih Wan
    Wu, Jiayi
    Ding, Shuning
    Lin, Caijin
    Chen, Xiaosong
    Huang, Ou
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    Zhu, Li
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2019, 145 (07) : 1877 - 1886